MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Clinical trials for MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to bridge patients to Life-Saving transplant
Disease control Recruiting nowThis study is testing a combination of drugs to see if it can better prepare patients with advanced blood cancers for a stem cell transplant from a donor. The goal is to control the aggressive cancer cells before the transplant, which may help the new donor cells take hold and fi…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 21:25 UTC
-
New drug combo trial aims to tame aggressive blood cancers
Disease control Recruiting nowThis study is testing whether adding a new drug called iadademstat to an existing treatment (ASTX727) works better for controlling advanced blood cancers. It will involve about 62 adults with specific aggressive forms of myeloproliferative neoplasms (MPNs) that have progressed. T…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC